Challenges in the Interpretation of Dengue Vaccine Trial Results by Rodriguez-Barraquer, I et al.
Viewpoints
Challenges in the Interpretation of Dengue Vaccine Trial
Results
Isabel Rodriguez-Barraquer1, Luis Mier-y-Teran-Romero2, Donald S. Burke3, Derek A. T. Cummings1*
1Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, United States of America, 2Nonlinear Systems Dynamics Section, Plasma Physics Division,
U.S. Naval Research Laboratory, Washington, D.C., United States of America, 3University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, United
States of America
Several hypotheses have been proposed
to explain the unexpected results of the
first completed efficacy clinical trial of a
vaccine against dengue virus [1]. Based on
intention-to-treat analyses, the vaccine was
efficacious in reducing the incidence of
clinical disease caused by dengue serotypes
1, 3, and 4, but failed to reduce the
incidence of dengue-2 (DENV-2). The
authors of the study propose potential
explanations including an antigenic mis-
match between the parental strain of the
DENV-2 component and currently circu-
lating DENV-2 viruses in Ratchaburi, an
increased role for immunity to nonstruc-
tural proteins in DENV-2 that this vaccine
does not induce, and a lack of correlation
of measured neutralizing antibody and
protective immunity [1].
However, we believe that in addition to
questioning the immune response elicited
by the vaccine, it is important to discuss
the interpretability of efficacy results for
dengue vaccine trials that are based
exclusively on clinical outcomes. The
study by Sabchareon measured vaccine
efficacy against clinically apparent infec-
tion (VEC). This is distinct from vaccine
efficacy against infection (VEI), and po-
tentially a very important distinction.
VEI is a function of the incidence of
infection in the control and vaccine groups
and measures the vaccine’s capacity to
induce an immune response that will
prevent infection. In contrast, VEC is a
function of the incidence of clinical disease
in the control and vaccine groups, and
depends not only on the incidence of
infection, but also on the probability of
developing clinical disease after infection.
VEC and VEI will only be exchangeable if
the probabilities of clinical disease (often
described as the symptomatic:asympto-
matic ratio) are equal in the control and
vaccine groups.
Dengue disease is caused by four
interacting viral serotypes. Risk factors
for symptomatic disease have not been
fully characterized. There is substantial
evidence that preexisting, naturally ac-
quired immunity against a heterologous
serotype is a significant risk-factor for the
development of clinical disease [2].
Whether vaccine-induced immunity acts
in the same way is not clear, though this is
possible and plausible [3]. If vaccine-
induced immunity does resemble naturally
acquired immunity, it clearly has the
potential to modify the probability of
clinical disease among vaccine recipients
and obscure the relationship between VEC
and VEI. Figure 1 illustrates an example of
how a vaccine with high VEI would seem
to be ineffective in a trial based only on
clinical outcomes.
To explore the agreement between
VEC and VEI under different assump-
tions of the impact of prior heterologous
immunity on the probability of symp-
tomatic disease, we developed an an-
alytical framework (details available in
Text S1). Our results suggest that VEC
often leads to large underestimates of
VEI but can also lead to overestimates
depending upon the tradeoff between
preventing infections and inducing im-
munity that can predispose individuals to
a more severe outcome (e.g., clinically
apparent instead of asymptomatic dis-
ease) (Figure 2). Discarding or moving
forward with vaccine candidates purely
on the basis of VEC could lead to
prematurely abandoning vaccines that
could have promising population-level
impacts or moving forward with an
overly optimistic estimate of a vaccine’s
impact.
The discrepancy between VEC and VEI
also raises questions about one of the
conclusion of this vaccine trial: that the
‘‘absence of any sign of disease enhance-
ment…in the presence of non-protective
immune responses’’ to DENV-2 serves as
evidence against vaccine-induced en-
hanced severity of disease. With the
inclusion of only clinical outcomes, it is
impossible to know what number of
individuals in the vaccine or control
groups experienced infection and thus
what fraction of infections experienced
clinical outcomes. Tradeoffs between pro-
tective immunity and immunity that may
predispose individuals to severe outcome
again obscure the results.
While we agree with WHO guidance
that clinical disease should be the primary
end point of dengue trials and thus VEC
the primary measure of vaccines [4],
knowledge of infection is critical to
correctly interpreting clinical vaccine effi-
cacy results, in particular for diseases like
dengue where the relationship between
infection and disease is not clear. Further-
more, estimates of the VEI will be
necessary to determine the proportion of
the population that needs to be vaccinated
in order to control transmission. We
acknowledge that measures of infection
(as measured by virological surveillance
among those not experiencing clinically
apparent infection, seroconversions, and/
or changes in serological responses over
time in those not experiencing clinically
apparent disease) are imperfect and re-
source intensive, but surveillance for
infection has been performed routinely in
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other cohort studies [5]. Design of current
and future dengue vaccine trials should
incorporate additional outcomes in order
to fully characterize vaccine candidates
given the complexities of the natural
history of dengue.
Supporting Information
Text S1 Description of the analytical
framework developed to explore the
agreement between VEC and VEI.
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Figure 1. Figure showing the lack of agreement that might exist between VEI and VEC. In this example, VEI is 0.7. However, since the
vaccine also increases the probability of symptomatic disease by a factor of 3.3, VEC is 0.
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Figure 2. Output from our analytical framework showing the relationship between VEI and VEC. For this example, we assumed the
following serotype-specific efficacies against infection: VEI1 = 0.6 (i.e., VEI for DENV1=0.6), VEI3 = 0.8, and VEI4 = 0.9. We explored a range of VEI against
dengue-2 (VEI2) (y-axis). The x-axis is the ratio of the probabilities of developing clinical disease in people with and without prior immunity, and hence
reflects the extent to which prior heterologous immunity (natural or vaccine acquired) modifies the probability of clinical disease. The background
color represents expected vaccine efficacy against clinically apparent infection for all serotypes (left panel) and for dengue-2 (right panel). Solid black
contours indicate the clinical vaccine efficacy VEC observed in the Ratchaburi trial [1] according to the intention-to-treat analysis. Dashed white
contours indicate levels of the ratio VEC2:VEI2. Thus, the 0.5 contour divides the regions where VEC2 underestimates VEI2 by a factor greater (above) or
lower (below) than 0.5. In this particular simulation, VEC always underestimates VEI.
doi:10.1371/journal.pntd.0002126.g002
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